FDA approves less-invasive LVAD for advanced HF
Medtronic announced that a left ventricular assist device for the treatment of patients with advanced HF has received approval from the FDA.
The approval of the LVAD (HeartWare HVAD, Medtronic) was based on data from the LATERAL trial, according to a press release from the company.
As Cardiology Today previously reported, patients with end-stage HF who have had a ventricular assist device implanted by a thoracotomy procedure had similar survival and adverse event profiles compared with historical data of patients who had the device implanted by a standard sternotomy approach.
“We have
The approval of the LVAD (HeartWare HVAD, Medtronic) was based on data from the LATERAL trial, according to a press release from the company.
As Cardiology Today previously reported, patients with end-stage HF who have had a ventricular assist device implanted by a thoracotomy procedure had similar survival and adverse event profiles compared with historical data of patients who had the device implanted by a standard sternotomy approach.
“We have